Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...

This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients ... invaluable to our board, and this ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...

LONDON - Aneurin Bevan University Health Board (ABUHB) in Wales has initiated a six-month pilot program for a new medical device known as Speedboat®, developed by Creo Medical (TASE:PMCN ...

A health board has become the first in Wales to implement a technology to treat Colon cancer, developed by Welsh med-tech company Creo Medical. Aneurin Bevan University Health Board (ABUHB) will pilot ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...

LONDON - Aneurin Bevan University Health Board (ABUHB) in Wales has initiated a six-month pilot program for a new medical device known as Speedboat®, developed by Creo Medical (TASE:PMCN) Group plc ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

Read more here. Board games are a great way to break the ice, whether you’re at a party or hosting a get-together with folks you haven’t seen in a while. But with so many options available ...